

Supplementary material

1 Simulation settings

For all patients we observe covariates x_1, \dots, x_8 , of which 4 are continuous and 4 are binary. More specifically,

$$\begin{aligned} x_1, \dots, x_4 &\sim N(0, 1) \\ x_5, \dots, x_8 &\sim B(1, 0.2) \end{aligned}$$

We first, generate the binary outcomes y for the untreated patients ($t_x = 0$), based on

$$P(y | \mathbf{x}, t_x = 0) = g(\beta_0 + \beta_1 x_1 + \dots + \beta_8 x_8) = g(lp_0), \quad (1)$$

where

$$g(x) = \frac{e^x}{1 + e^x}$$

For treated patients, outcomes are generated from:

$$P(y | \mathbf{x}, t_x = 1) = g(lp_1) \quad (2)$$

where

$$lp_1 = \gamma_2(lp_0 - c)^2 + \gamma_1(lp_0 - c) + \gamma_0$$

1.1 Base-case scenario

The base-case scenario assumes a constant odds ratio of 0.8 in favor of treatment. The simulated datasets are of size $n = 4250$, where treatment is allocated at random using a 50/50 split (80% power for the detection of an unadjusted OR of 0.8, assuming an event rate of 20% in the untreated arm). Outcome incidence in the untreated population is set at 20%. For the development of the prediction model we use the model defined in (1) including a constant treatment effect. When doing predictions, t_x is set to 0. The value of the true β is such that the above prediction model has an AUC of 0.75.

The previously defined targets are achieved when $\beta = (-2.08, 0.49, \dots, 0.49)^t$. For the derivations in the treatment arm we use $\gamma = (\log(0.8), 1, 0)^t$.

1.2 Deviations from base-case

We deviate from the base-case scenario in two ways. First, we alter the overall target settings of sample size, overall treatment effect and prediction model AUC. In a second stage, we consider settings that violate the assumption of a constant relative treatment effect, using a model-based approach.

For the first part, we consider:

- Sample size:
 - $n = 1064$
 - $n = 17000$
- Overall treatment effect:

- $OR = 0.5$
- $OR = 1$
- Prediction performance:
 - $AUC = 0.65$
 - $AUC = 0.85$

We set the true risk model coefficients to be $\beta = (-1.63, 0.26, \dots, 0.26)^t$ for $AUC = 0.65$ and $\beta = (-2.7, 0.82, \dots, 0.82)^t$ for $AUC = 0.85$. In both cases, β_0 is selected so that an event rate of 20% is maintained in the control arm.

For the second part linear and quadratic deviations from the assumption of constant relative effect are considered. We also consider different intensity levels of these deviations. The settings for these deviations are defined in Table S1 and result in the effects of Figure S1.




Figure S1: Linear and quadratic deviations from the base-case scenario of constant relative effect ($OR=0.8$)

In Figure S2 the absolute benefits observed based on different settings are presented. The base-case scenario is also presented as a reference.

Finally, we consider 3 additional scenarios of interaction of individual covariates with treatment. These scenarios include a 4 weak interactions ($OR_{t_x=1}/OR_{t_x=0} = 0.82$), 4 strong interactions ($OR_{t_x=1}/OR_{t_x=0} = 0.61$), and 2 weak and 2 strong interactions (Table S2).

1.3 Risk modeling

Merging treatment arms, we develop prediction models including a constant relative treatment effect:

$$E\{y | x, t_x\} = P(y | x, t_x) = g(\beta_0 + \beta_1 x_1 + \dots + \beta_8 x_8 + \gamma t_x) \quad (3)$$

Individualized predictions are derived setting $t_x = 0$.




Figure S2: Linear and quadratic deviations from the base-case scenario of constant relative effect (OR=0.8)

1.4 Approaches to individualize benefit predictions

1.4.1 Risk stratification

Derive a prediction model using the same approach as above and divide the population in equally sized risk-based subgroups. Estimate subgroup-specific absolute benefit from the observed absolute differences. Subject-specific benefit predictions are made by attributing to individuals their corresponding subgroup-specific estimate.

1.4.2 Constant treatment effect

Assuming a constant relative treatment effect, fit the adjusted model in (1.3). Then, an estimate of absolute benefit can be derived from

$$\hat{f}_{\text{benefit}}(lp \mid \mathbf{x}, \hat{\beta}) = g(lp) - g(lp + \hat{\gamma})$$

1.4.3 Linear interaction

The assumption of constant relative treatment effect is relaxed modeling a linear interaction of treatment with the risk linear predictor:

$$E\{y \mid \mathbf{x}, t_x, \hat{\beta}\} = g(lp + (\gamma_0 + \gamma_1 lp)t_x)$$

We predict absolute benefit from

$$\hat{f}_{\text{benefit}}(lp \mid \mathbf{x}, \hat{\beta}) = g(lp) - g(\gamma_0 + (1 + \gamma_1)lp)$$

1.4.4 Restricted cubic splines

Finally, we drop the linearity assumption and predict absolute benefit using smoothing with restricted cubic splines with 3, 4, and 5 knots. More specifically, we fit the model:

$$P(y = 1 \mid lp, t_x) = g(\beta_0 + \beta_{t_x} t_x + f_{RCS}(lp) + f_{RCS}(lp) \times t_x)$$

where

$$f_{RCS}(x) = \alpha_0 + \alpha_1 h_1(x) + \alpha_2 h_2(x) + \cdots + \alpha_{k-1} h_{k-1}(x)$$

with

$$h_{j+1}(x) = (x - t_j)^3 - (x - t_{k-1})_+ \frac{t_k - t_j}{t_k - t_{k-1}} + (x - t_k)_+^3 \frac{t_{k-1} - t_j}{t_k - t_{k-1}}$$

and t_1, \dots, t_k are the selected knots. We predict absolute benefit from

$$\hat{f}_{\text{benefit}}(lp \mid \boldsymbol{x}, \hat{\beta}) = P(y = 1 \mid lp, t_x = 0) - P(y = 1 \mid lp, t_x = 1)$$

Table S1:

Analysis ID				Baseline risk								True treatment effect				
Scenario	Effect	N	AUC	b0	b1	b2	b3	b4	b5	b6	b7	b8	g0	g1	g2	c
1	absent	4,250	75	-2.08	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.00	1.00	0.00	0
	absent	4,250	65	-1.63	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.00	1.00	0.00	0
	absent	4,250	85	-2.70	0.82	0.82	0.82	0.82	0.82	0.82	0.82	0.82	0.00	1.00	0.00	0
	absent	1,064	75	-2.08	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.00	1.00	0.00	0
	absent	1,064	65	-1.63	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.00	1.00	0.00	0
	absent	1,064	85	-2.70	0.82	0.82	0.82	0.82	0.82	0.82	0.82	0.82	0.00	1.00	0.00	0
	absent	17,000	75	-2.08	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.00	1.00	0.00	0
	absent	17,000	65	-1.63	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.00	1.00	0.00	0
	absent	17,000	85	-2.70	0.82	0.82	0.82	0.82	0.82	0.82	0.82	0.82	0.00	1.00	0.00	0
Constant treatment effect																
10	moderate	4,250	75	-2.08	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.49	-0.22	1.00	0.00	0
11	moderate	4,250	65	-1.63	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	-0.22	1.00	0.00	0
12	moderate	4,250	85	-2.70	0.82	0.82	0.82	0.82	0.82	0.82	0.82	0.82	-0.22	1.00	0.00	0
13	moderate	1,064	75	-2.08	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.49	-0.22	1.00	0.00	0
14	moderate	1,064	65	-1.63	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	-0.22	1.00	0.00	0
15	moderate	1,064	85	-2.70	0.82	0.82	0.82	0.82	0.82	0.82	0.82	0.82	-0.22	1.00	0.00	0
16	moderate	17,000	75	-2.08	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.49	-0.22	1.00	0.00	0
17	moderate	17,000	65	-1.63	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	-0.22	1.00	0.00	0
18	moderate	17,000	85	-2.70	0.82	0.82	0.82	0.82	0.82	0.82	0.82	0.82	-0.22	1.00	0.00	0
19	high	4,250	75	-2.08	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.49	-0.69	1.00	0.00	0
20	high	4,250	65	-1.63	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	-0.69	1.00	0.00	0
21	high	4,250	85	-2.70	0.82	0.82	0.82	0.82	0.82	0.82	0.82	0.82	-0.69	1.00	0.00	0
22	high	1,064	75	-2.08	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.49	-0.69	1.00	0.00	0
23	high	1,064	65	-1.63	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	-0.69	1.00	0.00	0
24	high	1,064	85	-2.70	0.82	0.82	0.82	0.82	0.82	0.82	0.82	0.82	-0.69	1.00	0.00	0
25	high	17,000	75	-2.08	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.49	-0.69	1.00	0.00	0
26	high	17,000	65	-1.63	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	-0.69	1.00	0.00	0
27	high	17,000	85	-2.70	0.82	0.82	0.82	0.82	0.82	0.82	0.82	0.82	-0.69	1.00	0.00	0
Linear deviation																
28	moderate	4,250	75	-2.08	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.49	-0.29	0.95	0.00	0
29	moderate	4,250	65	-1.63	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	-0.35	0.93	0.00	0
30	moderate	4,250	85	-2.70	0.82	0.82	0.82	0.82	0.82	0.82	0.82	0.82	-0.37	0.93	0.00	0
31	moderate	1,064	75	-2.08	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.49	-0.29	0.95	0.00	0

32	moderate	1,064	65	-1.63	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	-0.35	0.93	0.00	0
33	moderate	1,064	85	-2.70	0.82	0.82	0.82	0.82	0.82	0.82	0.82	0.82	-0.37	0.93	0.00	0
34	moderate	17,000	75	-2.08	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.49	-0.29	0.95	0.00	0
35	moderate	17,000	65	-1.63	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	-0.35	0.93	0.00	0
36	moderate	17,000	85	-2.70	0.82	0.82	0.82	0.82	0.82	0.82	0.82	0.82	-0.37	0.93	0.00	0
37	high	4,250	75	-2.08	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.49	-0.44	0.80	0.00	0
38	high	4,250	65	-1.63	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	-0.54	0.78	0.00	0
39	high	4,250	85	-2.70	0.82	0.82	0.82	0.82	0.82	0.82	0.82	0.82	-0.50	0.78	0.00	0
40	high	1,064	75	-2.08	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.49	-0.44	0.80	0.00	0
41	high	1,064	65	-1.63	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	-0.54	0.78	0.00	0
42	high	1,064	85	-2.70	0.82	0.82	0.82	0.82	0.82	0.82	0.82	0.82	-0.50	0.78	0.00	0
43	high	17,000	75	-2.08	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.49	-0.44	0.80	0.00	0
44	high	17,000	65	-1.63	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	-0.54	0.78	0.00	0
45	high	17,000	85	-2.70	0.82	0.82	0.82	0.82	0.82	0.82	0.82	0.82	-0.50	0.78	0.00	0
Quadratic deviation																
46	moderate	4,250	75	-2.08	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.49	-5.02	1.00	-0.01	-5
47	moderate	4,250	65	-1.63	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	-5.02	1.00	-0.02	-5
48	moderate	4,250	85	-2.70	0.82	0.82	0.82	0.82	0.82	0.82	0.82	0.82	-5.02	1.00	-0.02	-5
49	moderate	1,064	75	-2.08	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.49	-5.02	1.00	-0.01	-5
50	moderate	1,064	65	-1.63	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	-5.02	1.00	-0.02	-5
51	moderate	1,064	85	-2.70	0.82	0.82	0.82	0.82	0.82	0.82	0.82	0.82	-5.02	1.00	-0.02	-5
52	moderate	17,000	75	-2.08	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.49	-5.02	1.00	-0.01	-5
53	moderate	17,000	65	-1.63	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	-5.02	1.00	-0.02	-5
54	moderate	17,000	85	-2.70	0.82	0.82	0.82	0.82	0.82	0.82	0.82	0.82	-5.02	1.00	-0.02	-5
55	high	4,250	75	-2.08	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.49	-4.42	1.00	-0.05	-5
56	high	4,250	65	-1.63	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	-4.42	1.00	-0.06	-5
57	high	4,250	85	-2.70	0.82	0.82	0.82	0.82	0.82	0.82	0.82	0.82	-4.42	1.00	-0.06	-5
58	high	1,064	75	-2.08	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.49	-4.42	1.00	-0.05	-5
59	high	1,064	65	-1.63	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	-4.42	1.00	-0.06	-5
60	high	1,064	85	-2.70	0.82	0.82	0.82	0.82	0.82	0.82	0.82	0.82	-4.42	1.00	-0.06	-5
61	high	17,000	75	-2.08	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.49	-4.42	1.00	-0.05	-5
62	high	17,000	65	-1.63	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	-4.42	1.00	-0.06	-5
63	high	17,000	85	-2.70	0.82	0.82	0.82	0.82	0.82	0.82	0.82	0.82	-4.42	1.00	-0.06	-5

Table S2:

Analysis ID				Baseline risk								Coefficient in treatment arm				
Scenario	Effect	N	AUC	b0	b1	b2	b3	b4	b5	b6	b7	b8	g1	g2	g5	g6
64	weak	4,250	75	-2.08	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.49	-0.19	-0.19	-0.19	-0.19
65	strong	4,250	75	-2.08	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.49	-0.49	-0.49	-0.49	-0.49
66	mixed	4,250	75	-2.08	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.49	-0.19	-0.49	-0.19	-0.49

~

2 Results in scenarios with interactions

When we considered a set of 4 true linear treatment-covariate interactions the model containing a linear interaction with the prognostic index had the lowest median RMSE. We observed an increasing trend in prediction errors with increasing interaction intensity (Figure S3). The model with restricted cubic spline smoothing (3 knots) had very comparable performance to the linear interaction model. Increasing the flexibility of the smooth methods resulted in increasing median RMSE. These results may be explained by the fact that the interactions considered were linear, thus favoring the linear interaction model. More flexible approaches may be better suited for higher-order treatment-covariate interactions. Finally, the adaptive approach had adequate performance under all scenarios, resembling the performance of the best-performing approach every time.




Figure S3: Linear and quadratic deviations from the base-case scenario of constant relative effect (OR=0.8)

The constant treatment effects model, the linear interaction model and the model with RCS smoothing (3 knots) had the highest c-for-benefit across all scenarios (Figure S4). RCS smoothing with 4 or 5 knots did not improve performance. On the contrary, we observed an increasing trend in c-for-benefit variability, as was the case in the main text. The adaptive approach again had satisfactory performance.

Despite the very similar performance in terms of prediction errors, the linear interaction model resulted in better-calibrated benefit predictions compared to the rest of the methods (Figure S5). The constant




Figure S4: Linear and quadratic deviations from the base-case scenario of constant relative effect (OR=0.8)

treatment effects model had the highest median ICI-for-benefit across all scenario settings, which became more pronounced with increasing treatment-covariate interaction intensity.




Figure S5: Linear and quadratic deviations from the base-case scenario of constant relative effect (OR=0.8)

3 Case study

We fitted a logistic regression model to predict 30-day mortality after a myocardial infarction using data from the GUSTO-I trial. The risk factors modeled were age, Killip class, systolic blood pressure heart rate, primary MI and MI location. We restricted systolic blood pressure values to 120 mmHg and modeled heart rate using linear spline transformation with a knot at 50 beats per minute. A brief overview of the distribution of baseline characteristics is presented in Table S3. The coefficients of the model can be seen in Table S4. We used this model in the manuscript to derive baseline risk predictions to all patients of the study. For all patients we set the treatment indicator to 0, assuming a constant relative treatment effect. The model

Table S3: Baseline characteristics of the patients included in GUSTO-I trial.

	Tissue plasminogen activator (N=20162)	Streptokinase (N=10348)	Overall (N=30510)
Sex			
male	15070 (74.7%)	7725 (74.7%)	22795 (74.7%)
female	5092 (25.3%)	2623 (25.3%)	7715 (25.3%)
Age			
Mean (SD)	60.9 (11.9)	61.0 (12.0)	60.9 (11.9)
Median [Min, Max]	61.6 [19.0, 110]	61.6 [20.8, 108]	61.6 [19.0, 110]
Killip Class			
I	17209 (85.4%)	8798 (85.0%)	26007 (85.2%)
II	2529 (12.5%)	1328 (12.8%)	3857 (12.6%)
III	275 (1.4%)	142 (1.4%)	417 (1.4%)
IV	149 (0.7%)	80 (0.8%)	229 (0.8%)
Systolic Blood Pressure (mmHg)			
Mean (SD)	129 (23.9)	129 (24.0)	129 (23.9)
Median [Min, Max]	130 [0, 280]	130 [0, 280]	130 [0, 280]
MI Location			
Inferior	11623 (57.6%)	5959 (57.6%)	17582 (57.6%)
Other	695 (3.4%)	367 (3.5%)	1062 (3.5%)
Anterior	7844 (38.9%)	4022 (38.9%)	11866 (38.9%)
Heart Rate (beats/min)			
Mean (SD)	75.4 (17.8)	75.3 (17.8)	75.4 (17.8)
Median [Min, Max]	73.0 [1.00, 220]	73.0 [0, 205]	73.0 [0, 220]
Previous MI			
no	16842 (83.5%)	8610 (83.2%)	25452 (83.4%)
yes	3320 (16.5%)	1738 (16.8%)	5058 (16.6%)
Outcome			
Alive	18687 (92.7%)	9695 (93.7%)	28382 (93.0%)
Dead	1475 (7.3%)	653 (6.3%)	2128 (7.0%)

displayed very good internal validity (Table S5).

We used the derived prediction model to predict benefit of tPA to 30-day mortality using the data at hand. The models are presented in the main manuscript. All approaches displayed comparable discrimination for benefit, with the constant treatment effect model, the linear interaction model and the RCS (5 knots) model displaying the highest performance (Table S6). However, the linear interaction model and the RCS (5 knots) model were worse calibrated. The constant treatment effect model also had the best performance among the considered methods in terms of calibration for benefit.

Table S4: Coefficients of the prediction model for 30-day mortality after myocardial infarction (MI).

	Estimate	Std. Error	z value	Pr(> z)
(Intercept)	-3.0203	0.7973	-3.7882	0.0002
Treatment	-0.2080	0.0529	-3.9346	0.0001
Age	0.0769	0.0025	31.2797	0.0000
KILLIP (II)	0.6137	0.0589	10.4231	0.0000
KILLIP (III)	1.1610	0.1214	9.5658	0.0000
KILLIP (IV)	1.9213	0.1618	11.8718	0.0000
Systolic blood pressure	-0.0392	0.0019	-20.3316	0.0000
Pulse rate	-0.0242	0.0159	-1.5213	0.1282
Pulse rate'	0.0433	0.0162	2.6748	0.0075
Prior MI (yes)	0.4472	0.0562	7.9641	0.0000
MI location (other)	0.2863	0.1347	2.1261	0.0335
MI location (anterior)	0.5432	0.0511	10.6245	0.0000




Figure S6: Smooth calibration of the derived prediction model.

Table S5: Evaluation statistics of the prediction model for 30-day mortality in GUSTO-I.

Metric	Value
AUC	0.8153
Brier score	0.0556
Emax	0.0855
E90	0.0106
Eavg	0.0034

Table S6: Performance metrics of the different methods used to predict benefit of tPA on 30-day mortality using data from the GUSTO-I trial.

Model	C	ICI	AIC
constant treatment effect	0.5246	0.0104	9,335.700
linear interaction	0.5256	0.0115	9,340.258
RCS smoothing with 3 knots	0.5253	0.0117	9,341.727
RCS smoothing with 4 knots	0.5237	0.0123	9,334.331
RCS smoothing with 5 knots	0.5243	0.0121	9,336.732

Table S7: Rates at which the adaptive approach selected each model type.

type	effectSize	sampleSize	auc	treatment	risk	rcs
constant	absent	4,250	75	0.97	0.02	0.02
constant	absent	4,250	65	0.98	0.01	0.01
constant	absent	4,250	85	0.98	0.01	0.01
constant	absent	1,064	75	0.96	0.01	0.03
constant	absent	1,064	65	0.96	0.01	0.02
constant	absent	1,064	85	0.97	0.01	0.02
constant	absent	17,000	75	0.96	0.02	0.02
constant	absent	17,000	65	0.96	0.02	0.01
constant	absent	17,000	85	0.98	0.01	0.01
constant	moderate	4,250	75	0.97	0.01	0.02
constant	moderate	4,250	65	0.98	0.01	0.01
constant	moderate	4,250	85	0.98	0.01	0.01
constant	moderate	1,064	75	0.96	0.02	0.03
constant	moderate	1,064	65	0.97	0.01	0.02
constant	moderate	1,064	85	0.97	0.01	0.02
constant	moderate	17,000	75	0.97	0.01	0.02
constant	moderate	17,000	65	0.98	0.01	0.01
constant	moderate	17,000	85	0.99	0.00	0.01
constant	high	4,250	75	0.97	0.01	0.02
constant	high	4,250	65	0.98	0.01	0.01
constant	high	4,250	85	0.97	0.01	0.02
constant	high	1,064	75	0.97	0.01	0.02
constant	high	1,064	65	0.97	0.02	0.01
constant	high	1,064	85	0.98	0.01	0.01
constant	high	17,000	75	0.96	0.02	0.02

type	effectSize	sampleSize	auc	treatment	risk	rcs
constant	high	17,000	65	0.98	0.01	0.01
constant	high	17,000	85	0.97	0.02	0.01
linear	moderate	4,250	75	0.95	0.02	0.03
linear	moderate	4,250	65	0.98	0.02	0.00
linear	moderate	4,250	85	0.93	0.05	0.02
linear	moderate	1,064	75	0.96	0.02	0.02
linear	moderate	1,064	65	0.96	0.02	0.02
linear	moderate	1,064	85	0.95	0.02	0.02
linear	moderate	17,000	75	0.88	0.10	0.03
linear	moderate	17,000	65	0.93	0.05	0.03
linear	moderate	17,000	85	0.66	0.27	0.07
linear	high	4,250	75	0.56	0.35	0.09
linear	high	4,250	65	0.84	0.13	0.04
linear	high	4,250	85	0.26	0.63	0.12
linear	high	1,064	75	0.90	0.07	0.03
linear	high	1,064	65	0.93	0.04	0.03
linear	high	1,064	85	0.76	0.17	0.07
linear	high	17,000	75	0.02	0.83	0.15
linear	high	17,000	65	0.24	0.64	0.11
linear	high	17,000	85	0.00	0.89	0.11
quadratic	moderate	4,250	75	0.90	0.06	0.04
quadratic	moderate	4,250	65	0.93	0.06	0.02
quadratic	moderate	4,250	85	0.70	0.20	0.09
quadratic	moderate	1,064	75	0.94	0.03	0.03
quadratic	moderate	1,064	65	0.96	0.02	0.02
quadratic	moderate	1,064	85	0.89	0.07	0.04
quadratic	moderate	17,000	75	0.61	0.29	0.10
quadratic	moderate	17,000	65	0.78	0.18	0.05
quadratic	moderate	17,000	85	0.08	0.62	0.30
quadratic	high	4,250	75	0.02	0.68	0.29
quadratic	high	4,250	65	0.29	0.57	0.14
quadratic	high	4,250	85	0.00	0.16	0.84
quadratic	high	1,064	75	0.59	0.30	0.11
quadratic	high	1,064	65	0.83	0.12	0.05
quadratic	high	1,064	85	0.10	0.55	0.35

type	effectSize	sampleSize	auc	treatment	risk	rcs
quadratic	high	17,000	75	0.00	0.35	0.65
quadratic	high	17,000	65	0.00	0.77	0.23
quadratic	high	17,000	85	0.00	0.00	1.00
interaction	weak	4,250	75	0.71	0.22	0.07
interaction	strong	4,250	75	0.10	0.75	0.15
interaction	mixed	4,250	75	0.39	0.49	0.12




Figure S7: RMSE of the considered methods when there is no treatment effect. Each row contains the result for sample sizes of 1064, 4250 and 17000. Each column contains the results for AUC of the baseline risk prediction model of 0.65, 0.75 and 0.85.